Non-segmental vitiligo
Conditions
Interventions
Observation group:None
Sponsors
West China hospital Sichuan University
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Be 12 years old and above, regardless of gender, at the time of signing the informed consent form; 2. Study participants clinically diagnosed with non-segmental vitiligo with facial involvement, and the overall depigmentation area of the whole body does not exceed 10% BSA; 3. Agree to have no family plans during the study and for 4 weeks after the last dose and voluntarily use effective contraceptive measures; 4. Study participants voluntarily signed informed consent and agreed to regular follow-up visits.
Exclusion criteria
Exclusion criteria: 1. Suffering from other skin depigmentation diseases that affect the judgment of efficacy (such as pityriasis albicans, leprosy, post-inflammatory pigmentation Decreased, progressive macula hypomelanosis, anaemic nevus, chemical white skin disease and tinea versicolor, etc.); 2. More than 1/3 of the white spot area has white hair, or the white spot area has white hair and is evaluated based on clinical diagnosis and treatment experience to participate in the study. Investigate those who are less likely to benefit; 3. Allergy to the*utic drugs and excipients; 4. Study participation with known end-stage renal disease (ESRD) or undergoing renal replacement therapy (such as dialysis) person; 5. Participate in other clinical studies; 6. The investigator determined that it was not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of study participants achieving F-VASI 75 (facial vitiligo area score index improvement =75%);The improvements of RADS-25 and DASS-21 were compared with baseline; | — |
Countries
China
Contacts
Public ContactXian Jiang
West China hospital Sichuan University
Outcome results
None listed